

Active Biotech

[View the current Active Biotech Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/102-Active+Biotech.html)

(<http://www.bioportfolio.com/biocorporate/102-Active+Biotech.html>)

Contact Details:

PO Box 4215

Verwood

BH31 6XR

United Kingdom

Tel: +44 1202 823087

Fax: +44 1202 823336

Email:

Active Biotech AB is a Swedish biotechnology company focused on the research and development of pharmaceuticals and vaccines. Their core competence is knowledge of the human immune system.

Recent Publications by Active Biotech:



- [Increased degradation rate of nitrosoureas in media containing carbonate.](#)
The stability of two nitrosoureas, tauromustine and lomustine, has been... 16th October, 2008
Department of Preclinical Development, Active Biotech Research AB, P.O.- In Vitro Cell Dev Biol Anim. 2008 Oct 15. ([DOI Direct Link](#))
- [Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects.](#)
In this study we explored the possibility of improving the anti-tumor... 9th April, 2008
Active Biotech Research AB, P.O. Box 724, SE-220 07 Lund, Sweden.- Int Immunopharmacol. 2008 Mar;8(3):442-52. Epub 2007 Dec 7. ([DOI Direct Link](#))
- [Discovery of selective small-molecule CD80 inhibitors.](#)
Protein-protein interactions are widely found in biological systems... 19th August, 2007
Active Biotech Research AB, Lund, Sweden.- J Biomol Screen. 2007 Jun;12(4):464-72. Epub 2007 Apr 13. ([DOI Direct Link](#))
- [Determination of the immunomodulator laquinimod in human plasma by liquid chromatography/tandem mass spectrometry; development, validation and application of two methods in clinical pharmacokinetic profiling.](#)
Laquinimod (ABR-215062) is a synthetic compound currently undergoing... 20th January, 2007
Research and Development Laboratories, Active Biotech Research AB, Box- Rapid Commun Mass Spectrom. 2006;20(22):3313-8. ([DOI Direct Link](#))
- [Synthesis and reactivity of laquinimod, a quinoline-3-carboxamide: intramolecular transfer of the enol](#)

[proton to a nitrogen atom as a plausible mechanism for ketene formation.](#)

5-Chloro-N-ethyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinoline... 12th December, 2006
R&D Laboratories, Active Biotech Research AB, Box 724, SE-220 07 Lund,- J Org Chem. 2006 Feb
17;71(4):1658-67. ([DOI Direct Link](#))

- [Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod \(ABR-215062\) in IFN-beta k.o. and wild type mice.](#)

Laquinimod is a novel oral immunomodulatory substance, which is currently... 27th May, 2006
Active Biotech AB, Box 724, SE-220 07 Lund, Sweden.- J Neuroimmunol. 2006 Apr;173(1-2):69-78.
Epub 2006 Feb 10. ([DOI Direct Link](#))

- [In vitro metabolism and in vivo pharmacokinetics of quinoline 3-carboxamide derivatives in various species.](#)

The metabolism of a group of quinoline 3-carboxamide derivatives was... 4th October, 2005
Preclinical Development, Active Biotech Research AB, SE-220 07 Lund,- Xenobiotica. 2005
Mar;35(3):293-304. ([DOI Direct Link](#))

- [Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator.](#)

In the present study, the involvement of cytochrome P450 enzyme(s) in the... 30th August, 2005
Preclinical Development, Active Biotech Research AB, Box 724, SE-220 07- Drug Metab Dispos. 2005
Jun;33(6):866-72. Epub 2005 Mar 11. ([DOI Direct Link](#))

- [Influence of IGF-IR stimulation or blockade on proliferation of human renal cell carcinoma cell lines.](#)

Several tumors secrete insulin-like growth factors (IGFs) for autocrine... 3rd March, 2005
Active Biotech Research AB, Department of Cellular and Molecular Biology,- Int J Oncol. 2004
Nov;25(5):1327-36.

- [Identification of protein-protein interfaces implicated in CD80-CD28 costimulatory signaling.](#)

The B7 ligands CD80 and CD86 on APCs deliver either costimulatory or... 7th August, 2004
Active Biotech Research, Lund, Sweden.- J Immunol. 2004 Jun 1;172(11):6803-9.

- [The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses.](#)

BACKGROUND: Histone deacetylase inhibitors (HDACIs) induce... 28th May, 2004
Department of Biology, Active Biotech Research AB, P.O. Box 724, SE-22007- BMC Cancer. 2003 Nov
9;3:30. ([DOI Direct Link](#))

- [Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.](#)

Roquinimex-related 3-quinolinecarboxamide derivatives were prepared and... 20th May, 2004
Active Biotech Research AB, Box 724, SE-220 07 Lund, Sweden.- J Med Chem. 2004 Apr
8;47(8):2075-88. ([DOI Direct Link](#))

- [Interplay between superantigens and immunoreceptors.](#)

Superantigens (SAGs) cause a massive T-cell proliferation by... 7th May, 2004
Active Biotech Research AB, Lund, Sweden.- Scand J Immunol. 2004 Apr;59(4):345-55. ([DOI Direct Link](#))

- [A fast and parallel route to cyclic isothioureas and guanidines with use of microwave-assisted chemistry.](#)

A fast and simple approach to novel cyclic isothioureas and related... 5th May, 2004
Department of Drug Discovery, Active Biotech AB, Box 724, 22007 Lund,- J Org Chem. 2004 Mar
5;69(5):1571-80. ([DOI Direct Link](#))

- [Bcl-3 and NFkappaB p50-p50 homodimers act as transcriptional repressors in tolerant CD4+ T cells.](#)

The transcriptional events that control T cell tolerance are still poorly... 5th May, 2004
Active Biotech Research Center, Scheelevagen 22, S-223 63 Lund, Sweden.- J Biol Chem. 2004 Feb
27;279(9):8460-8. Epub 2003 Dec 10. ([DOI Direct Link](#))

- [Beta-Cell Appoints New CEO](#)
Pharma Live: Dec 22 2008 4:56PM Matching: active biotech
- [Active Biotech's cancer drug promising in combo therapy](#)
PharmaBiz: Dec 17 2008 11:43AM Matching: active biotech
- [Active Biotech AB's Cancer Project ANYARA: Combination with Established Tumor Therapies Promising](#)
BioSpace: Dec 11 2008 1:09AM Matching: active biotech
- [Active Biotech's Cancer Project ANYARA: Combination with Established Tumor Therapies Promising](#)
Street Insider: Dec 10 2008 7:55AM Matching: active biotech
- [Active Biotech: Active Biotech's Cancer Project ANYARA: Combination with Established Tumor Therapies Promising](#)
Market Wire: Dec 10 2008 8:02AM Matching: active biotech
- [Active Biotech's Cancer Project Anyara: Combination with Established Tumor Therapies Promising](#)
Pharma Live: Dec 10 2008 5:49PM Matching: active biotech
- [Active Biotech's Cancer Project ANYARA: Combination with Established Tumor Therapies Promising](#)
TMC Net: Dec 10 2008 10:36AM Matching: active biotech
- [Active Biotech's Cancer Project ANYARA: Combination with Established Tumor Therapies Promising](#)
Houston Chronicle: Dec 10 2008 9:55AM Matching: active biotech
- [Active Biotech's Cancer Project ANYARA: Combination with Established Tumor Therapies Promising](#)
Marketwire via Yahoo!: Dec 10 2008 7:56AM Matching: active biotech
- [Active Biotech's Cancer Project ANYARA: Combination with Established Tumor Therapies Promising](#)
Yahoo! Canada: Dec 10 2008 7:50AM Matching: active biotech
- [Active Biotech's Cancer Project ANYARA: Combination with Established Tumor Therapies Promising](#)
MarketWatch: Dec 10 2008 7:49AM Matching: active biotech
- [Active Biotech's Cancer Project ANYARA: Combination with Established Tumor Therapies Promising](#)
Therapeutics Daily: Dec 10 2008 12:13PM Matching: active biotech
- [Active Biotech's Cancer Project ANYARA: Combination with Established Tumor Therapies Promising](#)
Genetic Engineering News: Dec 10 2008 8:58AM Matching: active biotech
- [Active Biotech's Cancer Project ANYARA: Combination with Established Tumor Therapies Promising](#)
Market Wire: Dec 10 2008 7:55AM Matching: active biotech
- [Active Biotech's election committee appointed](#)
MarketWatch: Nov 28 2008 9:39AM Matching: active biotech

Active Biotech Patents:



- 7425623- [Antibody with specificity for colon cancer](#)
- 6727062- [Identification of target structures E.G. in vivo selection method for a phage library](#)
- 6642249- [Immunomodulating compounds](#)
- 6605616- [Quinoline derivatives](#)

- 6593343- [Quinoline derivatives](#)
- 6518312- [Immune enhancement](#)
- 6395750- [Drugs for the treatment of malignant tumors](#)
- 6133285- [Quinoline derivatives](#)
- 6121287- [Quinoline derivatives](#)
- 6875869- [Process for the manufacture of quinoline derivatives](#)
- 6962694- [Cytolysis of target cells by superantigen conjugates inducing T-cell activation](#)
- 7339059- [Benzofurans and indols](#)
- 7291612- [Immunomodulatory compounds](#)
- 7226601- [Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate](#)
- 7226595- [Modified Chimeric superantigens and their use](#)
- 7189816- [Compounds](#)
- 7125554- [Engineered superantigen for human therapy](#)
- 7081456- [Immunomodulatory compounds](#)
- 7074831- [Compounds, methods for their preparation and use thereof](#)
- 6077851- [Quinoline derivatives](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

